- Human Biospecimens
- Biospecimen Contributors
April 13, 2021
It happens in roughly 12 percent of U.S. lung cancer diagnoses: The patient had never smoked tobacco. Worldwide, half of female lung cancer patients are never-smokers compared with 15% of men. Women never-smokers are more than twice as likely to develop lung cancer as never-smoking men.
The phenomenon of lung cancer in never-smokers is detailed here in STAT, notably by Sharon Begley, an acclaimed science journalist who died of lung cancer five days after it published. She, too, had never smoked.
The proportion of lung cancer patients who’ve never smoked is rising, she reported. It’s uncertain how much of that increase is due to a decline in smoking. If a certain number of lung cancer cases occur in never-smokers year after year but the pool of smokers is declining, the share of never-smokers would grow as a matter of simple math.
Either way, “doctors and public health experts have been slow to recognize this trend, however, and now there is growing pressure to understand how never-smokers’ disease differs from that of smokers, and to review whether screening guidelines need revision” wrote Begley.
Drugs work better in smokers
In some ways, lung cancer can be worse for never-smokers than for smokers. The drugs tend to work better in smokers because the tumors are often more visible to the immune system. “Because never-smokers have fewer tumor mutations, it’s harder to find them,” Begley wrote.
Health care is now grappling with how to think about lung cancer in never-smokers. Lung cancer screening isn’t currently recommended for never-smokers – the argument being that cost outweighs the benefit. And though treatment guidelines are the same for smokers and never-smokers, that doesn’t mean the condition is the same.
Some have proposed that lung cancer in women never-smokers should be considered a separate disease. One company is working on a drug to treat it.
Human biospecimens available for deeper investigation
We support researchers who are studying cancer of all types in hopes of developing new treatments and diagnostics. We provide these researchers the human biospecimens they need through the iSpecimen Marketplace. Users can search for and select biofluids, tissues and cells, refining their requests by a long list of patient characteristics, including
We’ll continue doing whatever we can to support the continuing fight against all cancers, in men and women, and in smokers and nonsmokers, whatever the suspected cause.
Learn about the iSpecimen Marketplace where you can browse millions of richly annotated, de-identified human tissue and biofluid biospecimens, in addition to hematopoietic and immune cell products and COVID-19 samples. You can join for free and creating a login is easy. Request a quote or custom collection today.